Investigations	8 (3.4)
Alanine aminotransferase increased	3 (1.3)
Gamma-glutamyltransferase increased	3 (1.3)
Platelet count decreased	3 (1.3)
Aspartate aminotransferase increased	2 (0.9)
Neutrophil count decreased	1 (0.4)
White blood cell count decreased	1 (0.4)
Skin and subcutaneous tissue disorders	8 (3.4)
Palmar-plantar erythrodysaesthesia syndrome	7 (3.0)
Haemorrhage subcutaneous	1 (0.4)
Renal and urinary disorders	5 (2.2)
Proteinuria	4 (1.7)
Renal failure	1 (0.4)
Gastrointestinal disorders	2 (0.9)
Diarrhoea	2 (0.9)
Metabolism and nutrition disorders	2 (0.9)
Decreased appetite	1 (0.4)
Hypokalaemia	1 (0.4)
Vascular disorders	2 (0.9)
Hypertension	2 (0.9)
General disorders and administration site conditions	1 (0.4)
Asthenia	1 (0.4)
Musculoskeletal and connective tissue disorders	1 (0.4)
Bone pain	1 (0.4)
